RecruitingPhase 3NCT06660394
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Studying Dravet syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Longboard Pharmaceuticals
- Intervention
- LP352(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 2-65 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Arkansas Children's Hospital - PIN, Little Rock, Arkansas, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- The Stanford Division of Child Neurology, Palo Alto, California, United States
- UCSF Children's Hospital, San Francisco, California, United States
- Children's Hospital Colorado., Aurora, Colorado, United States
- NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
- Nicklaus Children's Hospital - PIN, Miami, Florida, United States
- Research Institute of Orlando LLC, Orlando, Florida, United States
- Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States
- Rare Disease Research, LLC - Atlanta - RDR - PIN, Atlanta, Georgia, United States
- Ann and Robert H Lurie Childrens Hospital of Chicago - PIN, Chicago, Illinois, United States
- Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
- Mayo Clinic - PIN, Rochester, Minnesota, United States
- Institute of Neurology and Neurosurgery at Saint Barnabas, LLC, Livingston, New Jersey, United States
- Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave, Morristown, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06660394 on ClinicalTrials.govOther trials for Dravet syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07251673Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc
- RECRUITINGPHASE4NCT06598449Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGPHASE3NCT06118255A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeUCB BIOSCIENCES, Inc.
- RECRUITINGPHASE1, PHASE2NCT05419492A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06283212A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Encoded Therapeutics
- ENROLLING BY INVITATIONNANCT06371794EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype HeterogeneityFondazione Policlinico Universitario Agostino Gemelli IRCCS